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Introduction
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that 
act as intermediate signaling molecules, translating signals 
from extracellular stimuli into intracellular signals that regu-
late multiple signal transduction pathways.1 These pathways 
regulate many essential cell processes, including cell growth, 
differentiation, proliferation, motility, and metabolism.2–5 
Somatic mutations that result in the activation of PI3K are 
frequently detected in cancer. Indeed, reports suggest that 
deregulation of the PI3K signaling pathway is associated with 
tumor development in .30% of cancers.6–9 As a result, a large 
body of research has focused on developing potent, selective, 
and efficacious PI3K pathway inhibitors, which are currently 
at different stages of development.5,10,11
With the advent of rationally designed molecular cancer 
therapeutics, our understanding of drug discovery in cancer 
has undertaken a paradigm shift.12 The goal of drug develop-
ment strategies is to obtain maximal biological effect on the 
target, which will translate into therapeutic efficacy. Therefore, 
a significant need has emerged for molecular biomarkers that 
can accurately assess the underlying mechanisms of action and 
pharmacodynamic (PD) effects of the drug. These so-called 
PD biomarkers provide confirmation of the pharmacologic 
effects of a novel antitumor compound on its intended tar-
get, pathway, and downstream biological processes and often 
assess whether a compound is engaging its molecular target in 
the expected manner. In clinical trials, PD biomarkers may 
allow (i) proof of mechanism (ie, evidence that the drug hits 
its intended target), (ii) proof of concept (evidence that hitting 
the drug target alters the biology of the tumor), (iii) selec-
tion of optimal biological dosing, and (iv) understanding of 
response/resistance mechanisms. In addition, PD biomar kers, 
in association with pharmacokinetic (PK) parameters of drug 
exposure, can be linked to therapeutic effects in what is known 
as a pharmacological audit trail.12
Other biomarkers that are also applied in clinical drug 
development include (i) predictive biomarkers, which can 
guide the selection of patients likely to respond to a particular 
therapy, (ii) prognostic biomarkers, which estimate the likely 
disease course and, hence, the most appropriate management 
strategy, and (iii) surrogate response biomarkers, which moni-
tor a patient’s response to treatment.
Here, we review the biomarkers that have been applied 
in early-phase clinical trials of PI3K pathway inhibitors. We 
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focus primarily on PD endpoints that demonstrate target 
modulation, including invasive molecular assays, circulating 
biomarkers, and functional imaging technology.
The PI3K/AKt/mtor signaling Pathway
The PI3K family consists of three distinct classes (I–III), each 
with different structures and substrate specificities. Class I 
PI3Ks are further divided into subclasses IA and IB, and it is 
the IA subclass that is most frequently activated in cancer.13,14 
Class IA molecules are heterodimers consisting of a p110 
catalytic subunit complexed with a p85 regulatory subunit.15 
There are three isoforms of the p110 catalytic subunit (α, β, 
and δ), encoded by PIK3CA, PIK3CB, and PIK3CD genes, 
respectively. In addition, the p85 regulatory subunit consists 
of five isoforms, encoded by three PIK3R genes (Fig. 1).16,17
In the absence of an extracellular activating signal, 
p85 interacts with p110, which results in inhibition of p110 
kinase activity. Following receptor tyrosine kinase (RTK) or 
G-protein-coupled receptor activation, the p85–p110 heterodi-
mer is recruited to the plasma membrane, together with interac-
tion between RTK phosphotyrosine residues and SH2 domains 
on p85, resulting in release of the basal p85 inhibition of the 
p110 catalytic subunit and activation of class IA PI3K. Acti-
vated PI3K phosphorylates phosphatidylinositol 4,5-biphos-
phate (PIP2) to phosphatidylinositol 3,4,5- triphosphate (PIP3), 
which then acts as a second messenger leading to the recruit-
ment of AKT and its subsequent phosphorylation by PDK1 
and mammalian target of rapamycin complex 2 (mTORC2).18 
AKT stimulates glycolysis by activating glycolytic enzymes 
and regulating glucose transporters.19 This mechanism drives 
tumor cells to avidly consume glucose as a source of ATP.20 
In addition, activated AKT promotes cell growth and sur-
vival by a number of mechanisms, including (1) inhibition 
of proapoptotic proteins of the B-cell leukemia/lymphoma-2 
(BCL-2) family; (2) transcription of antiapoptotic genes, 
BCL2-Like 11 (BIM) and Fas Ligand (FASLG), via transcription 
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figure 1. The Pi3K/aKT/mTor signaling pathway and examples of drugs targeting each of its components. 
Note: rsK, 90 kDa ribosomal protein s6 kinase. adapted by permission from macmillan Publishers ltd: nature reviews clinical oncology, rodon et al.28, 
copyright 2013.
abbreviations: 4e-BP1, eukaryotic translation initiation factor 4e-binding protein 1; BaD, Bcl-2 antagonist of cell death; cDKn1, cyclin-dependent 
kinase inhibitor 1; Faslg, Fas antigen ligand; Foxo, forkhead box o; gFr, growth factor receptor; gsK3, glycogen synthase kinase-3; HiF1, hypoxia-
inducible factor 1; inPP4B, type ii inositol 3,4-bisphosphate 4-phosphatase; mTorc, mTor complex; PDK1, 3-phosphoinositide-dependent protein 
kinase 1; PiP2, phosphatidylinositol (4,5)-biphosphate; PiP3, phosphatidylinositol (3,4,5)-triphosphate; Pras40, proline-rich aKT1 substrate 1; PTen, 
phosphatase and tensin homolog; rPs6, 40s ribosomal protein s6.
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factors forkhead box O (FoxO) and nuclear factor-kappaB; 
(3) enhanced degradation of proapoptotic p53 via increased 
cytoplasmic availability of mdm218,21,22 regulation of the 
cyclin-dependent kinase inhibitors such as CDKN1A and 
CDKN1B (also known as p21 and p27) through activation 
of cyclin D1 and cyclin E1 and transcription factors such as 
Jun proto-oncogene (JUN) and V-Myc avian myelocytoma-
tosis viral oncogene homolog (MYC).
The mammalian target of rapamycin complex 1 (mTORC1)/
S6 kinase (S6K) axis and downstream effectors, such as 
eukaryote translation initiation factor 4E-binding protein 1 
(4E-BP1) and 40S ribosomal protein S6 (RPS6), regulate some 
of these downstream functions of AKT.23 mTORC1 is a com-
plex consisting of raptor, mLST8, and proline-rich Akt sub-
strate 40 (PRAS40). mTORC1 is activated by AKT via the 
inhibition of tuberous sclerosis 1/2 (TSC1/2). AKT phospho-
rylates TSC2, thus inhibiting TSC1/2; it also phosphorylates 
PRAS40, thus stimulating mTORC1.
Finally, the tumor suppressor molecules phosphatase and 
tensin homolog protein (PTEN) and inositol polyphosphate, 
4-phosphatase type II, a protein encoded by INPP4B, are the 
most important downregulators of the PI3K pathway.24,25 
PTEN dephosphorylates PIP3 to PIP2, whereas INPP4B 
dephosphorylates PIP2 to PIP.21 Since both these products 
inhibit PI3K-dependent AKT activation,26 the loss of PTEN 
or INPP4B results in activation of AKT.
PI3K/AKt/mtor Pathway Aberrations in cancer
The PI3K signaling pathway is frequently deregulated in 
human cancer.17,27 The comprehensive review by Rodon et al.28 
provides a full list of mutations and the frequency of each 
alteration in different tumors. Aberrant activation of PI3K sig-
naling occurs by a number of mechanisms, the most important 
of which are (i) loss of function of PTEN through mutation, 
microRNA expression, or epigenetic silencing, (ii) mutation 
or amplification of PIK3CA, (iii) amplification or mutation of 
AKT isoforms, or (iv) pathway activation by RTKs and Ras.1,2
There are several mechanisms through which decreased 
PTEN expression can occur, including loss of heterozygos-
ity on chromosome 10q and PTEN mutation.29 Unlike other 
tumor suppressor genes, such as p53, biallelic inactivation is 
not required for the suppression of PTEN activity; rather, 
haploinsufficiency may suffice in promoting tumorigenesis. 
Alternative mechanisms of somatic loss of PTEN activ-
ity include homozygous deletion and epigenetic silencing 
via promoter methylation. Functional PTEN loss has been 
found in a number of cancers, including endometrial cancer, 
melanoma, prostate cancer, and glioblastoma, and appears to 
be important in cancer progression.29–34
Mutations or amplifications of PIK3CA, encoding the 
catalytic p110α subunit of class IA PI3K, are common in sev-
eral human cancers including cervical cancer and squamous 
lung cancer, providing cells with a growth advantage and 
promoting tumor progression.1,16,34,35 Although mutations 
affecting the p85a regulatory subunit are less frequent, they 
have been found in up to 10% of human glioblastomas and 
,5% of colon and ovarian carcinomas.36,37
A single amino acid substitution, E17K, in the lipid-
binding PH domain of AKT1 has been observed in seven 
human cancers, including breast, colorectal, lung, and ovarian 
cancers.38 In addition, AKT2 overexpression has been identi-
fied in colorectal cancers. It is proposed that AKT2 promotes 
cellular survival and growth and that loss of AKT1 promotes 
cellular invasion and metastasis, possibly by shifting the bal-
ance of signaling through AKT2.39,40
In addition to somatic mutations of PTEN, PIK3CA, 
PIK3R1, and AKT, some cancers have amplifications of AKT1, 
AKT2, and PIK3CA; however, it is not clear if these amplifi-
cations have a significant impact on clinical outcome.
Inhibitors of the PI3K/AKt/mtor signaling 
Pathway
Numerous compounds have been developed to inhibit differ-
ent nodes in the PI3K/AKT/mTOR signaling pathway. These 
include PI3K inhibitors (subdivided into pan-PI3K inhibitors, 
isoform-selective PI3K inhibitors, and dual PI3K/mTOR 
inhibitors), mTOR inhibitors (divided into allosteric inhibi-
tors [rapalogues] and ATP-competitive inhibitors), and AKT 
inhibitors (including allosteric inhibitors and ATP-competi-
tive AKT inhibitors). A description of each of these classes of 
inhibitor and a discussion of some of the PD biomarkers used 
in THEIR evaluation IN phase I trials are explained later. 
Table 1 provides a comprehensive summary of PD biomarker 
evaluations reported in phase I studies of all PI3K/AKT/
mTOR signaling pathway inhibitors in current development.
Inhibitors of the PI3K/AKT/mTOR signaling pathway 
have similar toxicity profiles, which include rash, hyperglyce-
mia, gastrointestinal disturbances (eg, nausea, vomiting, diar-
rhea, anorexia, and dysgeusia), alopecia, mucositis, fatigue, 
thromboembolism, cytopenias, and liver enzyme elevations.
PI3K inhibitors. Pan-class I PI3K inhibitors. The earliest 
agents to enter clinical development were the pan-class I inhibi-
tors of PI3K, which directly inhibit p110 kinase activity by acting 
as ATP mimetics, binding competitively and reversibly to the 
p110 ATP-binding pocket. Of the pan-class I PI3K inhibitors 
in clinical development, BKM120 (buparlisib) is the furthest 
developed and is being extensively evaluated in hormone-
positive breast cancer, often in combination with endocrine 
therapy.41,42 Buparlisib has potent, pan-class I PI3K inhibitory 
PROPERTIES against p110-α, -β, -δ, and -γ enzymes at 
IC50 of 52, 166, 116, and 262 nM, respectively.43 Other pan-
class I PI3K inhibitors in clinical development include XL147 
(IC50 of 39, 36, 23, and 383 nM against p110-α, -β, -δ, and 
-γ, respectively), GDC-0941 (pictilisib; IC50 of 3 nM against 
p110-α and -δ enzymes), BAY80–6946 (copanlisib; IC50 
of 0.469 nM against p110-α and 3.72 nM against p110-β), 
PX-866 (sonolisib; IC50 of 0.1–88 nM), and CH5132799 (IC50 
of 14 nM against p110-α).44–49
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In the phase I dose-escalation and expansion study of 
BKM120 in patients with advanced solid tumors, there was 
clear demonstration of inhibition of phosphorylation of AKT, 
4E-BP1, and S6 in posttreatment tumor biopsies, confirm-
ing that BKM120 was capable of inhibiting the PI3K path-
way in tumor tissue. Furthermore, BKM120 induced partial 
metabolic responses by fluorodeoxyglucose positron emission 
tomography (18F-FDG PET) in 21 of 54 evaluable patients 
after 28 days of treatment, demonstrating the capability of 
18F-FDG PET as a PD biomarker; however, no association 
with progression-free survival, best response as per Response 
Evaluation Criteria in Solid Tumors (RECIST), or best per-
cent change in CT scan was identified.42 Dose-dependent 
inhibition of phosphorylation of S6 in the skin with single-
agent BKM120 has been reported.41,42,50 Indeed, the greatest 
reduction in phosphorylated S6 was associated with the best 
clinical response, highlighting phosphorylated S6 levels in the 
skin as a potentially useful surrogate biomarker of response to 
PI3K inhibition.50
In the phase I study of pictilisib, in addition to the 
decreases in AKT phosphorylation in platelet-rich plasma 
(PRP) and tumor, and the reduction in S6 phosphorylation 
observed in tumor (described earlier) following pictilisib 
treatment, other PD biomarkers also demonstrated evidence 
of target modulation.44 Following treatment, there was a sta-
tistically significant increase in plasma insulin and glucose 
levels at one hour from baseline, and 18F-FDG PET imaging 
showed a reduction from baseline of 18F-FDG-tracer uptake 
at dose levels $45 mg.44
Isoform-selective PI3K inhibitors. Novel PI3K inhibitors 
that are isoform specific have generated much enthusiasm 
owing to the hypothesized advantage that they may have 
fewer toxicities when compared with the pan-class I inhibi-
tors, allowing these agents to be tolerated at doses that may 
result in more complete inhibition of kinase activity. In addi-
tion, data suggest that the pro-tumor effects of different 
genetic alterations of the PI3K pathway may signal preferen-
tially through specific isoforms of p110. For example, HER2-
amplified breast carcinoma may depend primarily on p110α,51 
and the effects of PTEN loss largely depend on p110β in 
models of prostatic intraepithelial neoplasia.52 Therefore, there 
is interest in the activity of PI3Kα inhibitors (such as BYL719 
[alpelisib] and MLN1117) in cancers with PIK3CA mutations 
and PI3Kβ inhibitors (such as AZD8186, GSK2636771, and 
SAR26030153–57) in tumors with PTEN loss. Furthermore, 
p110δ is thought to be a dominant isoform in the lympho-
cytic lineage; indeed, PI3Kδ inhibitors (CAL-101 [Idela-
lisib] and AMG319) have shown promise in patients with 
chronic lymphocytic leukemia.57 A randomized double-blind 
placebo-controlled phase III study of CAL-101 (idelalisib) in 
combination with rituximab in patients with relapsed CLL 
demonstrated that the combination of rituximab and idelalisib 
led to greater disease-free survival, treatment response rate, 
and survival compared to rituximab plus placebo.58
In the first-in-human dose-escalation study of MLN117, 
doses of 200–900 mg suppressed phosphorylation of 4E-BP1 
and S6 in the skin by up to ∼100% and 70%–90%, respec-
tively, at ∼3 hours post single dose.59 However, evaluation of 
target inhibition in the tumor itself has not yet been reported 
for this drug.
‘For PI3Kδ inhibitors in hematological malignancies, 
reductions in plasma chemokine concentrations have been 
reported as important PD biomarkers.60,61 For example, plasma 
concentrations of CLL-derived chemokines such as CCL3, 
CCL4, CCL22, and CCL17, which were elevated at baseline, 
demonstrated significant decreases within one cycle of CAL-
101 (idelalisib) treatment.62
Dual PI3K/mTOR inhibitors. The development of dual 
PI3K/mTOR inhibitors was based on the known structural 
similarities between the ATP-binding domain of p110 and 
the catalytic domain of mTOR. Unlike rapalogue mTOR 
inhibitors, these agents are active site inhibitors of mTOR 
and have the advantage of inhibiting the kinase activity of 
mTOR regardless of whether it is in complex with TORC1 
or TORC2. Since mTOR responds to a variety of signals 
besides PI3K/AKT, these dual inhibitors are thought to have a 
broader activity in cancers in which PI3K/AKT is not the pri-
mary driver of mTOR activity. Finally, unlike the rapalogues, 
these agents might be able to inhibit TORC1 activity while 
preventing feedback activation of PI3K. Several dual PI3K/
mTOR inhibitors, such as XL765 (voxtalisib; IC50 of 157, 39, 
113, 9, and 43 nM for mTOR, p110-α, -β, -γ, and -δ, respec-
tively), GDC-0980 (apitolisib; IC50 of 17, 5, 27, 7, and 4 nM 
for mTOR, p110-α, -β, -γ, and -δ, respectively), BEZ235 
(dactolisib; IC50 of 6, 4, 5, 7, and 75 nM for mTOR, p110-α, 
-β, -γ, and -δ, respectively), and PF04691502 (IC50 of 16, 
1.8, 2.1, 1.6, and 1.9 nM for mTOR, p110-α, -β, -γ, and -δ, 
respectively), are now in clinical development.63–66 However, 
although some objective tumor responses have been observed, 
the activity of these agents thus far has been modest, and no 
clinical trial with either a pan-class I PI3K inhibitor or dual 
PI3K/mTOR inhibitor has reported robust clinical activity, 
even in tumors with known genetic alterations.67 Possible rea-
sons for this include (1) uncertainty as to the extent of down-
stream phosphoprotein biomarker modulation required to 
result in efficacy in patients; (2) insufficient target inhibition; 
(3) inappropriate biomarker selection; or (4) inappropriate 
patient selection. Furthermore, it is conceivable that continu-
ous inhibition of PI3K/mTOR may result in an adaptation 
favoring cell growth.64 For certain conditions harboring driver 
mutations, such as BCR-ABL in chronic myeloid leukemia, 
the continued inhibition of kinase activity provided by higher 
trough concentrations of targeted therapy results in more 
favorable clinical outcomes.68,69 However, in other malignan-
cies, models of drug resistance are challenging the requirement 
for continuous inhibition.70 For dual PI3K/mTOR inhibitors, 
further studies are required to determine whether selective 
pressures are in operation.
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The phase I study of PF04691502 exemplified the use 
of diverse PD biomarkers in a single study.64 The analyses 
were performed on paired tumor biopsies, paired hair fol-
licle samples, and blood. Posttreatment tumor biopsies and 
hair follicle samples demonstrated reductions in phosphory-
lation of AKTS473, AKTT308, FKHRT24/FKHRL1T32, and 
STAT3Y705or AKTS473, PRAS40T246, and STAT3Y705 on 
day 21 of treatment cycle 1. In addition, increases in blood glu-
cose, c-peptide, and insulin levels, which generally occurred 
by day 8 of the first treatment cycle, were also consistent with 
PI3K/mTOR pathway inhibition.64
AKt inhibitors. AKT inhibitors in clinical development 
are of two main classes: allosteric inhibitors such as MK2206 
and ATP-competitive AKT inhibitors such as GDC-0068, 
GSK795, and AZD5363.71–74 Thus far, these agents are all pan-
isoform inhibitors of AKT. In early-phase clinical trials, the 
clinical activity of these agents has been modest thus far, and 
questions regarding appropriate patient selection remain. For 
example, it was suggested that certain PIK3CA mutations result 
in relatively low activation of AKT in comparison to PTEN 
loss.75 Thus, these agents may be more appropriately directed to 
those cancers with AKT alterations and PTEN loss.
The first-in-man phase I trial of MK2206 incorporated 
detailed PK-PD studies in both normal and tumor tissues 
to confirm adequate drug exposure with concomitant tar-
get and pathway blockade.71 Average steady-state trough 
MK2206 concentrations at the recommended phase II dose 
(RP2D) were greater than the concentrations required for 
70% inhibition of AKTS473 phosphorylation in whole blood, 
a level identified in preclinical models as associated with 
antitumor activity. PD analyses demonstrated AKT signal-
ing blockade in both tumor and surrogate tissues. Studies 
assessing phosphorylation of AKTS473 in tumor samples pro-
vided evidence of target blockade at the RP2D. In addition, 
studies in hair follicles also indicated that the phosphory-
lated Thr246 signal on PRAS40 was effectively blocked at 
this dose level.71
mtor inhibitors. Allosteric inhibitors (rapalogues). 
Allosteric inhibitors describe rapamycin (sirolimus) and its 
analogs, temsirolimus, everolimus, and ridaforolimus (for-
merly known as deforolimus).76 They inhibit the mTORC1 
kinase by binding to an abundant intracellular protein, 
FKBP12, forming a complex that inhibits mTOR signaling. 
Rapalogues initially demonstrated efficacy as a single agent 
for the treatment of renal cell carcinoma and progressive 
advanced pancreatic neuroendocrine tumors.77,78 Other indi-
cations with significant clinical activities include mantle cell 
lymphoma, sarcoma, and ER-positive breast cancer in com-
bination with hormone therapy.79
A phase I study of everolimus used the PD effects on 
mTOR-dependent pathways (4E-BP1 pathway: phosphory-
lated 4E-BP1 and eIF4G; S6K1 pathway: phosphorylated S6) 
in paired pre- and on-therapy tumor and skin biopsies, in 
addition to the safety profile of the drug, in order to determine 
the optimal dose and schedule of everolimus.80 Tabernero et al 
demonstrated that daily dosing resulted in near complete inhi-
bition of phosphorylation of S6 at both dose levels tested, while 
inhibition of phosphorylation of eIF4G and 4E-BP1 was more 
profound at the 10 mg dose level when compared with the 
5 mg dose level. In the weekly schedule, complete inhibition 
of S6 phosphorylation was again seen at all the studied dose 
levels. However, complete and prolonged inhibition of phos-
phorylation of eIF4G was only observed at doses $50 mg. 
Based on these data, the authors recommended everolimus 
treatment at either 10 mg/day or 50 mg/week.
ATP-competitive inhibitors. mTOR catalytic site inhibi-
tors directly target the kinase domain of mTOR and, there-
fore, impede the activity of both mTORC1 and mTORC2 
kinases. The theory behind dual mTORC1/2 inhibition 
is that it may prevent compensatory feedback activation 
of AKT upon mTORC1 inhibition as occurs with rapa-
logues.81 mTORC1/2 inhibitors in clinical development 
include OSI-027, AZD2014, CC-223, MLN-0128/INK128, 
and AZD8055.82–86
In the phase I study of AZD2014, the PD profile demon-
strated target engagement in both surrogate and tumor tis-
sues.82 Proof-of-mechanism biomarkers of mTORC1 and 
mTORC2 inhibition, such as A 40%–45% reduction in levels 
of phosphorylated 4E-BP1 in peripheral blood mononuclear 
cells (PBMCs) and A 37%–62% reduction in phosphorylated 
AKT in PRP, respectively, were seen at 2 and 8 hours but 
recovered at 24 hours following a single dose of AZD2014. 
Therefore, this, together with the PK profile demonstrating 
an elimination half-life of approximately three hours sup-
ported a twice-a-day schedule. Importantly, at the maximum 
tolerated dose (MTD), the authors also demonstrated reduced 
levels of phosphorylated S6 (∼20%–100%) in all evaluable 
posttreatment biopsies and reduction of phosphorylated AKT 
levels (20%–50%) in 3/4 assessable posttreatment biopsies.82 
In addition to these proof-of-mechanism PD biomarkers, 
proof-of-concept biomarkers such as reduction of proliferation 
(Ki67) and reduction in metabolism (18F-FDG PET) also sup-
ported evidence of target inhibition in tumor.82 At the MTD, 
five of nine patients showed reduction in Ki67 expression of 
50%–100%. In addition, 8 of 11 patients showed a reduction 
of change in maximum standardized uptake value (SUVmax), 
with three patients attaining a partial response (30% reduc-
tion in SUVmax).82
In the phase I trial of OSI-027, an oral dual mTORC1/2 
inhibitor, there was inhibition of phosphorylation of 4E- 
 BP1T37/T46 by .60% in PBMCs, but no evidence of objec-
tive responses.84 In contrast, the phase I study of the dual 
mTORC1/mTORC2 inhibitor, AZD8055, used phosphory-
lation of AKT in PBMCs as a biomarker of mTORC1 and 
mTORC2 inhibition. Unfortunately, the assay in PBMCs was 
rendered challenging due to very low levels of AKT phospho-
rylation at baseline; therefore, no conclusions could be drawn 
on mTORC2 inhibition in PBMCs in this study.83
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PI3K/AKt/mtor Pathway biomarkers
Clinical trials of PI3K/AKT/mTOR pathway inhibitors have 
utilized several biomarker strategies, including PD biomark-
ers of signaling output, eg, inhibition of downstream phos-
phorylated proteins, indirect PD biomarkers of metabolic 
effect, eg, glucose metabolism markers, and functional imag-
ing monitoring biomarkers, eg, 18F-FDG PET (Table 2). In 
addition, many trials are now using predictive biomarkers, eg, 
PIK3CA or AKT mutations, and PTEN loss, for the purpose 
of identifying subpopulations of patients who are most likely 
to respond to PI3K/AKT/mTOR pathway inhibitors.
biomarkers of PI3K pathway signaling. During early- 
phase clinical trials of novel PI3K/AKT/mTOR pathway 
inhibitors, the degree and duration of PI3K pathway inhibition 
Table 2. Pi3K/aKT/mTor pathway biomarkers and their potential disadvantages.
BIoMaRKER USE PoTENTIaL DISaDvaNTagES
Biomarkers of PI3K pathway signaling 
Phosphorylation of aKT at the residues  
Thr308 and ser473;
Demonstrates target modulation Imperfect at predicting efficacy in  
patients since only modest response  
rates are observed despite achievement  
of predicted tumour target inhibition of  
phosphorylation
Phosphorylation of the aKT substrate  
Pras40 at Thr246
Demonstrates target modulation
Phosphorylation of 4eBP1 at ser65 and Thr70 Demonstrates target modulation
Phosphorylation of rPs6 at ser240 and  
ser244
Demonstrates target modulation
Biomarkers of metabolic effect
Fasting plasma glucose levels indirect determination of pathway modulation insulin and c-peptide may be superior  
to fasting glucose levels, because  
increased insulin/c-peptide release can  
effectively compensate for decreased  
glucose transport and metabolism due to  
Pi3K inhibition at lower doses
Plasma insulin levels indirect determination of pathway modulation
Plasma c-peptide levels indirect determination of pathway modulation
functional imaging biomarkers 
18F-FDg PeT (i)    indirect determination of pathway  
modulation
(ii) surrogate marker of response
Uncertain role as a predictive biomarker  
due to lack of association between  
18F-FDg-PeT changes and tumour  
response evaluated by standard cross- 
sectional imaging (eg, cT).
18F-FlT PeT (i)    indirect determination of anti-proliferative  
effects
(ii) surrogate marker of response
not yet been utilized in a trial of a Pi3K  
pathway inhibitor
magnetic resonance spectroscopy surrogate marker of response not yet been utilized in a trial of a Pi3K  
pathway inhibitor
Diffusion-Weighted- and Dynamic  
contrast enhanced-mri
surrogate marker of response not yet been utilized in a trial of a Pi3K  
pathway inhibitor
Circulating biomarkers
circulating tumour cells (i)   surrogate marker of response
(ii)  molecular characterisation for ‘real time’  
demonstration of target modulation
cells in the blood will be exposed to  
plasma drug concentrations, which may  
or may not be the same as drug levels 
achieved in solid tumours. 
cell-free Dna/circulating tumour  
Dna
(i)   surrogate marker of early response
(ii)  Predict sensitivity to Pi3K/aKT/mTor  
pathway inhibitors
low plasma Dna levels may mean  
mutations are missed, and clonal  
evolution of detected mutations
circulating markers of cell death  
and angiogenesis 
surrogate marker of cell death and  
angiogenesis
intrapatient variability is high 
Predictive biomarkers
mutations in PIK3CA Predict sensitivity to Pi3K/aKT/mTor  
pathway inhibitors
(i)   The complexities of the pathway and 
its feedback loops mean that clear 
prediction of response to genotype is 
difficult.
(ii)    Use of incorrectly standardized or 
unvalidated assays may mean that 
driver mutations are missed
(iii)  coexistence of mutations related to 
resistance
(iv)  Presence of intratumour 
heterogeneity
loss of PTen expression Predict sensitivity to Pi3K/aKT/mTor  
pathway inhibitors
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has been established by measuring PD biomarkers primarily 
through evaluating the degree of inhibition of phosphoryla-
tion in downstream proteins. Since quantification of a bio-
marker in close proximity to PI3K (eg, PIP3) has not been 
feasible in the clinical setting, and measurement of AKT in 
tissues requires stringent sampling and handling conditions 
to avoid variability (which may not be possible in the con-
text of a multicenter clinical trial), other targets have been 
preferable in biomarker development for PI3K/AKT/mTOR 
pathway inhibitors.28,41 These have included assessment of 
(i) phosphorylation of AKT at the residues Thr308 and Ser473, 
(ii) phosphorylation of the AKT substrate PRAS40 at Thr246, 
(iii) phosphorylation of 4E-BP1 at Ser65 and Thr70, and 
(iv) phosphorylation of RPS6 at Ser240 and Ser244.28 How-
ever, it is important to note that phosphorylation of 4E-BP1 
and RPS6 can also be regulated by enhanced RAS/RAF/
ERK/mTORC1 activity, thereby potentially masking PD 
effects.23 Nevertheless, biomarker analyses from phase I studies 
have consistently demonstrated a dose- and time- dependent 
decrease in phosphorylation of markers such as AKT, 4E-BP1, 
and RPS6 when PI3K/AKT/mTOR inhibitors are used at the 
MTD, thereby demonstrating target modulation.
Preclinical tumor target phosphorylation data (percent-
age inhibition of phosphorylation and duration of inhibition 
of phosphorylation) are often employed to predict the dura-
tion and magnitude to which the pathway should be inhibited 
in patients, in order to achieve meaningful efficacy. However, 
in a number of phase I studies of PI3K/AKT/mTOR path-
way inhibitors, although predicted tumor target inhibition 
of phosphorylation was achieved at the RP2D, only modest 
response rates were observed. This highlights the imperfection 
of phosphoprotein biomarker modulation at predicting efficacy 
in patients and demonstrates the need to utilize separate bio-
markers to define PD effect and predict therapeutic efficacy.44
biomarkers of metabolic effect. Given the role of the 
PI3K pathway in physiological glucose metabolism, many 
studies of PI3K/AKT/mTOR inhibitors have included 
biomarkers of metabolic effect, which are indirect PD bio-
markers.87,88 Fasting glucose, insulin, and C-peptide levels in 
plasma, and glucose uptake using 18F-FDG PET (see later), have 
all been evaluated in the determination of target engagement 
and pathway modulation.41 Inhibition of PI3K abrogates the 
actions of insulin, mainly mediated by the PI3K p110α iso-
form, resulting in hyperglycemia and a compensatory release 
of insulin and C-peptide. Hyperglycemia has, therefore, com-
monly been used as a PD biomarker of PI3K pathway inhi-
bition; however, Bendell et al suggest that reduced plasma 
C-peptide levels may provide a better, indirect biomarker, 
since in their phase I study of BKM120 in patients with 
advanced solid tumors, increases in fasting C-peptide were 
detected at doses lower than those associated with hyperg-
lycemia, suggesting that increased insulin/C-peptide release 
can effectively compensate for decreased glucose transport and 
metabolism due to PI3K inhibition at lower doses.41
In a more recent phase I study of BKM120 in patients 
with advanced solid tumors, the analysis of glucose metab-
olism biomarkers (fasting plasma glucose, insulin, and 
C-peptide) supported the observation that BKM120 inhibits 
the PI3K pathway and perturbs glucose metabolism; however, 
a clear relationship between these biomarkers and the dose of 
BKM120 administered or the degree of pathway inhibition 
was not established.42 Further work is ongoing to establish the 
utility of biomarkers such as C-peptide as indicators of PI3K 
inhibitor activity.
Functional imaging biomarkers. Given the issues 
related to acquisition of tumor tissue for evaluation of PD 
biomarkers (including the need for repeated invasive biopsies, 
sampling errors, and bias due to tumor heterogeneity) and the 
limitations of surrogate tissue (see later), functional imaging 
has emerged as a novel method for evaluating the PD effects 
of PI3K pathway drugs.89,90 Functional imaging biomark-
ers have the potential to quantify biological characteristics 
of tumors and measure on- and off-target effects and allow 
serial, noninvasive assessments of whole tumor, which is par-
ticularly important in the context of inter- and intrapatient 
tumor heterogeneity. In addition, utilization of functional 
imaging could be used to guide assessment of both optimal 
biological dose and drug schedule.
Functional surrogate response imaging biomarkers for 
PI3K pathway inhibitor drugs have included 18F-FDG PET, 
39-deoxy-39-[18F]-fluorothymidine (18F-FLT) PET, MR spec-
troscopy, and diffusion-weighted- (DW) or dynamic contrast- 
enhanced- (DCE) MRI.
18F-FDG PET. Since AKT activation disrupts transcrip-
tion of the glucose transporter GLUT1 and its translocation to 
the plasma membrane, and also promotes glucose utilization 
independent of the effects on cell proliferation, 18F-FDG PET 
has been proposed as a PD biomarker for assessing efficacy of 
on-target inhibition of the PI3K/AKT pathway.91 In addition, 
early reductions in uptake on 18F-FDG PET (SUVmax from 
baseline) have been demonstrated to be a predictor of change 
in tumor burden, and therefore 18F-FDG PET can also be 
utilized as a predictive biomarker.92 18F-FDG PET has been 
incorporated into biomarker evaluations in several preclinical 
and clinical studies of PI3K and/or MEK inhibitor therapy. 
For example, it has been shown to be a surrogate marker 
of sensitivity to PI3K inhibition by the dual PI3K/mTOR 
inhibitor NVP-BEZ235 and the pan-class I PI3K inhibitor, 
NVP-BKM120, in human head and neck squamous cell car-
cinoma and mouse mammary 3D tumor spheroids in vitro.93 
In addition, 18F-FDG PET has been shown to be a surrogate 
marker of response following treatment with the pan-isoform 
PI3K inhibitor LY294002 or the dual PI3K/mTOR inhibitors 
PF04691502 and NVP-BEZ235 in colorectal, lung, and ovar-
ian tumor xenografts and/or mouse models in vivo.94–96
Furthermore, a decrease in uptake on 18F-FDG PET has 
been observed in several phase I clinical trials following PI3K/
AKT/mTOR inhibitor treatment.41,42,46 However, whether 
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the cause of this decrease is related to a direct effect of PI3K 
inhibition on glucose uptake (therefore, acting as a PD bio-
marker), or an antitumor effect (thus, acting as a predictive 
biomarker) is not yet known, and in some cases, both can have 
a role, as seen with mTOR inhibitors.91,97
In a recent phase I study, BKM120 administration insti-
gated partial metabolic responses detected by 18F-FDG PET 
(a .25% decrease in 18F-FDG uptake) in 39% of evaluable 
patients after 28 days of treatment; however, no association 
with progression-free survival or best response was identified. 
The authors suggested that the effect of PI3K inhibitors on 
glucose metabolism, the small number of patients and responses 
observed, and the highly heterogeneous range of patients and 
tumor types treated might have explained why 18F-FDG PET 
was unable to predict response to therapy in this study, despite 
demonstrating capability as a PD biomarker.42
In the phase I study of pictilisib (GDC-0941), par-
tial metabolic responses detected by 18F-FDG PET were 
observed in 7 of 32 evaluable patients.44 18F-FDG PET imag-
ing showed a reduction from baseline of tracer uptake at dose 
levels $45 mg with an overall median change in SUVmax of 
−13%, thereby confirming some degree of pathway modu-
lation.44 However, an association between 18F-FDG PET 
changes and RECIST response was not detected in this trial, 
highlighting the uncertainties of the role of 18F-FDG as a 
predictive biomarker.
18F-FLT PET. The fluorine-modified thymidine analog, 
18F-FLT, also represents a promising proof-of-concept anti-
proliferative PD and surrogate response biomarker for PI3K 
pathway inhibitor therapy. 18F-FLT PET is used for detect-
ing antiproliferative effects, since it is a thymidine analog, 
whose accumulation in cells is determined by the expression 
and activity of the enzyme thymidine kinase 1 and specific 
nucleoside transporters, both of which are under the control 
of S-phase cell cycle regulators.98 Furthermore, the uptake of 
18F-FLT PET has been shown to correlate with standard pro-
liferation markers, such as Ki67, TK1, and BrdU uptake.99–102 
Using 18F-FLT PET, changes in proliferation compared to 
baseline have been demonstrated in a variety of human tumor 
xenografts as early as 18, 24, and 120 hours after using either 
single-agent class I selective PI3K inhibitor GDC-0941 (pic-
tilisib) or MEK inhibitor PD0325901.89,90,103,104 Furthermore, 
in human xenograft tumor-bearing mice, the combination of 
the class I selective PI3K inhibitor pictilisib with the MEK 
inhibitor PD0325901 resulted in superior efficacy when com-
pared with controls, and this correlated with a subsequent 
decrease in tumor 18F-FLT uptake measured by PET just two 
days after treatment.98 18F-FLT PET has not yet been uti-
lized in a trial of a PI3K pathway inhibitor; however, it has 
been incorporated into a clinical trial of the MEK inhibi-
tor AZD6244 (selumetinib) as a single agent.105 In this pilot 
study, 18F-FLT PET scans were performed in four patients at 
baseline and after two weeks of treatment with selumetinib. 
FLT uptake in tumor was compared to CT scans at baseline 
and eight weeks to evaluate the utility of 18F-FLT PET as an 
early predictor of response. In two patients, changes in FLT 
uptake as early as after two weeks of treatment were consistent 
with CT results after eight weeks.105
Magnetic resonance spectroscopy. Cancer cells are known to 
reprogram their metabolism to facilitate tumor growth and 
survival by alteration of signaling pathways, which lead to 
alterations in glucose, glutamine, and lipid metabolism.20,106 
As discussed earlier, the PI3K/AKT/mTOR signaling path-
way is a master regulator of enzymes involved in glucose, glu-
tamine, and lipid metabolism.107,108 Therefore, inhibition of the 
PI3K signaling pathway impacts on the levels and/or activities 
of these enzymes.109 Magnetic resonance spectroscopy (MRS) 
is a technique that has recently been used in the clinical set-
ting to study cancer metabolism. It offers the opportunity to 
investigate metabolic components of cells and tissues in physi-
ological environments, noninvasively and without the use of 
radioactive reagents. In addition, since it produces spatial 
mapping of metabolites, MRS can overcome the challenges 
of tumor heterogeneity. These data are represented by a spec-
trum, in which the peaks correspond to different metabolites 
wherein peak areas can be measured and metabolite concen-
trations quantified. MRS is now being increasingly used for 
monitoring tumor cell metabolism and alterations in response 
to therapy in cultured cells, animal models, and patients.
Metabolic effects of PI3K inhibition in cancer have been 
studied in vitro and in vivo.110 Using nuclear magnetic reso-
nance (NMR), altered choline metabolism has been demon-
strated in response to inhibition of the PI3K signaling pathway 
with LY294002, wortmannin, and the selective dual pan-class I 
PI3K/mTOR inhibitor PI-103 in adult human cancer cell mod-
els.111,112 Distinct metabolic changes have been demonstrated 
using in vitro 1H- and phosphorus (31P)-NMR following PI3K 
pathway inhibition by PI-103 and pan-class I PI3K inhibitor 
GDC-0941 in pediatric glioblastoma cell lines. These included 
a decrease in the levels of lactate, phosphocholine (PC), and 
total choline.109 Moestue et al demonstrated, using ex vivo 
high-resolution magic angle spinning MRS, that response to 
PI3K inhibition in a breast cancer basal-like xenograft was 
associated with reduced lactate concentration and increased 
concentration of PC, glycerophosphocholine (GPC), and glu-
cose.113 The magnitude of the metabolic response was reflected 
by the inhibition of cancer cell proliferation and the reduction 
in phosphorylation of AKT ser473 level.113 Lactate, PC, and 
GPC can potentially be imaged noninvasively in vivo using 
MRS and may, therefore, be valuable biomarkers for early 
monitoring of response to PI3K inhibition. However, to date, 
the authors are not aware of any utilization of MRS in early-
phase clinical trials for PI3K pathway inhibitors.
Diffusion-weighted- and dynamic contrast-enhanced-MRI. 
DW-MRI can be used to measure the apparent diffusion 
coefficient (ADC) of water molecules and has been proposed 
as a marker for tissue cellularity.114 Treatment-induced cell 
death can be reflected by increased ADC values even before 
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significant tumor volume changes occur,114,115 and DW-MRI 
is, therefore, suggested as a method for measuring early treat-
ment response.116 DCE-MRI investigates the vascularization 
of a tissue by measuring signal enhancement curves after intra-
venous administration of a contrast agent and can be used to 
measure the changes in tumor blood flow, vascular permeabil-
ity, and extracellular extravascular and vascular volumes.117,118 
Both DW-MRI and DCE-MRI have been proposed as tools 
for measuring response to PI3K pathway inhibitors and have 
been evaluated in preclinical in vivo models.119–121
In a recent study, ADC was found to be a useful bio-
marker for response to the dual PI3K-mTOR inhibitor 
BEZ235 in an ovarian cancer xenograft model.119 In the same 
study, DCE-MRI, which provides information on tumor 
perfusion and vascular permeability also proved to be a use-
ful biomarker for response. The parameter ve is a measure of 
the extravascular extracellular space and, similar to ADC, 
may be related to the cellular density of the tumor tissue. In 
another recent study, Sampath et al.122 showed that response 
to the PI3K/mTOR inhibitor GDC-0980 was associated 
with increased ve.122 Despite these promising data, this func-
tional imaging modality has not yet been used in clinical tri-
als in this setting.
tumor versus surrogate biomarkers. Assessments of PD 
biomarkers of signaling output have classically required the 
collection of serial tumor biopsies; however, for solid tumors, 
this can be challenging. Therefore, researchers have explored 
using normal tissues, such as the skin, PBMCs, PRP, and 
plucked hair follicles, as POTENTIAL SURROGATES for 
tumor tissues. These minimally invasive sampling methods 
may reduce the risks associated with repeated tumor biopsies 
and enable serial determinations of drug effects, thus mini-
mizing the impact of inter- and intrapatient variability on 
such results. However, such surrogate methods are hampered 
by (i) requirement of the therapeutic target of interest to be 
highly expressed in normal tissues; (ii) differences in drug 
penetration and concentrations between normal and tumor 
tissues due to likely differences in tissue architecture; (iii) 
possible differences in gene expression between tissues; (iv) 
normal tissues lacking somatic mutations in the oncogenic 
target; (v) mutant enzymes in tumor tissue leading to sig-
nificant differences in drug sensitivity when compared with 
wild-type enzymes in normal tissues; and (vi) possible differ-
ences in signal transduction pathway regulation in tumors to 
normal cells.123–125
For example, in the phase I study of the pan-PI3K inhibi-
tor pictilisib (GDC-0941), a 90% decrease in AKT phospho-
rylation was detected in PRP at up to three hours postdose at 
the RP2D.44 In patient tumors, although at the highest level 
of drug exposure a .75% decrease in S6 phosphorylation and 
100% reduction in AKT phosphorylation were detected, a 
direct correlation between pictilisib exposure and decrease in 
S6 and AKT phosphorylation in tumors was less clear.44 In 
contrast to the consistent dose–response relationship in PRP, 
this lack of consistent target modulation in tumor at lower drug 
exposures was thought to be possibly related to different assay 
conditions, together with disparities in drug concentrations 
between normal and tumor tissues due to likely differences in 
tissue architecture and hemodynamics.
In a phase I study of the dual PI3K-mTOR inhibitor 
BGT226, the observed PD effects were also inconsistent 
between tumor tissue and skin.126 At BGT226 doses .80 mg, 
PI3K pathway inhibition was evident in skin biopsies as deter-
mined by a reduction in phosphorylation of S6 (Ser240/244) 
by 37%–64%. However, reductions in phosphorylation of S6/
AKT in tumors were not seen in all samples, and no biopsies 
were performed at doses .80 mg, making further interpreta-
tion difficult.126 This example illustrates that as collection of 
solid tumor biopsies is challenging, it is imperative to ensure 
that tumor tissue samples are always obtained at the MTD.
These differences also highlight both the importance 
of evaluating multiple PD biomarkers to comprehensively 
evaluate the overall pharmacological effects of the drug, and 
the danger of overinterpretation results from a single PD 
marker evaluation.
circulating biomarkers. Alternative methods for the 
evaluation of PD biomarkers of PI3K/AKT/mTOR path-
way inhibition include circulating tumor cells (CTCs), cell-
free DNA/circulating tumor DNA (ctDNA), and circulating 
markers of cell death and angiogenesis.
Circulating tumor cells. A promising development in trans-
lational cancer medicine has been the emergence of CTCs as 
a minimally invasive multifunctional biomarker. CTCs in 
peripheral blood originate from solid tumors and are involved 
in the process of hematogenous metastatic spread to distant 
sites to establish metastases. The potential use of CTCs as bio-
markers is not only confined to their enumeration (and there-
fore as a surrogate of response) but also includes their routine 
molecular characterization. The assessment of CTC-based PD 
biomarkers has the potential for rapidly demonstrating proof 
of mechanism during the clinical development of molecularly 
targeted anticancer therapeutics in real time.
However, one potential challenge in using CTCs for PD 
studies is that, similar to other surrogate tissue biomarkers, 
cells in the blood will be exposed to plasma drug concentra-
tions, which may or may not be the same as the drug levels 
achieved in solid tumors. Therefore, when interpreting PD 
data from CTCs, the PK data are critical and must be used 
in conjunction.
Western blot analyses of S6K1, phosphorylated-S6K1, 
and mTOR in CTCs were used as PD biomarkers in a recent 
phase II trial of the mTOR inhibitor sirolimus given in combi-
nation with trastuzumab for HER2-positive metastatic breast 
cancer.127 Unfortunately, no statistically significant correlation 
between response and posttreatment change in levels of the 
mTOR pathway biomarkers was detected in CTCs.127 CTC 
analyses have otherwise not yet been used in clinical trials in 
this setting.
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Cell-free DNA/ctDNA. Cell-free fragments of DNA are 
shed into the bloodstream by cells undergoing apoptosis or 
necrosis, and in patients, a small proportion (,1%) of the 
fragmented DNA in the circulation is derived directly from 
the tumor.128 Recent advances in sequencing technologies 
have enhanced the sensitivity and accuracy of DNA analysis, 
allowing for the genotyping of somatic genomic alterations in 
circulating cell-free DNA. Cell-free ctDNA contains genetic 
defects identical to those of the tumors themselves, enabling 
the detection of cancer-associated genetic alterations, includ-
ing point mutations, chromosomal rearrangements, ampli-
fications, and aneuploidy. Indeed, ctDNA can be identified 
and distinguished from normal cell-free DNA by testing 
for genetic mutations that are tumor specific. Furthermore, 
ctDNA levels have correlated with changes in tumor burden 
in a number of different malignancies.128,129 Thus, ctDNA has 
the potential to serve as a noninvasive tool, as a biomarker of 
early response, and as a predictive biomarker.
Potential drawbacks with this method include low plasma 
DNA levels, which may mean that mutations are missed, and 
also clonal evolution of detected mutations. As yet, in the con-
text of PD biomarkers of PI3K/AKT/mTOR pathway inhi-
bition, both CTC and ctDNA approaches have been more 
exploratory. However, these biomarker strategies are likely to 
be increasingly utilized in the future.
Circulating markers of cell death and angiogenesis. 
Circulating full-length and caspase-cleaved cytokeratin 
18 (CK18) are considered biomarkers of anticancer therapy-
induced cell death, measured using a combination of M30 
and M65 enzyme-linked immunosorbent assays (ELISAs).130 
M30 measures caspase-cleaved CK18 produced during apop-
tosis, and M65 measures the levels of both caspase-cleaved 
and intact CK18, the latter of which is released from cells 
undergoing necrosis. Circulating M30 and M65 and mark-
ers of angiogenesis (BFGF, PLGF, SVEGFR1, SVEGFR2, 
and VEGF) have been evaluated in early-phase clinical trials 
of PI3K pathway inhibitors.42,126 In general, intrapatient vari-
ability in these markers has been found to be high, and there-
fore, statistical relationships between pre- and post-treatment 
levels have not been confirmed.42
Predictive biomarkers. Preclinical data of PI3K path-
way inhibitors have supported the hypothesis that tumors 
with PIK3CA mutations or PTEN loss are more sensitive 
to PI3K/AKT inhibitors.131–133 However, the complexities 
of the pathway and its feedback loops mean that clear pre-
diction of response to genotype is difficult. For example, 
for the pan-class I PI3K inhibitor BKM120, studies dem-
onstrated that inhibition of PI3K had significant effects 
on cells carrying mutations of PIK3CA, whereas cells 
with PTEN or KRAS aberrations were not as sensitive.134 
Although triple- negative breast cancer subtypes with 
PIK3CA mutations were found to be sensitive to the dual 
PI3K/mTOR inhibitor, BEZ235, again the loss of PTEN 
did not predict response.135
Nevertheless, these preclinical studies have encouraged 
the enrichment of clinical trials with patients whose tumors 
harbor mutations in PIK3CA and PTEN or have loss 
of PTEN expression.131,136–138 Some pooled analyses of 
these clinical studies have suggested a correlation between 
molecular alterations in the PI3K pathway and antitumor 
effect,41,47,71 whereas others have suggested no such correla-
tion.139 The inconclusive predictive value of PIK3CA, PTEN, 
KRAS, or BRAF mutations for delineating the clinical value 
of PI3K/AKT/mTOR pathway inhibitors may be due to sev-
eral reasons. First, tumors without PI3K alterations might 
have responded because early detection methods were based 
on a limited number of assays and were unable to detect other 
alterations that could be driving sensitivity, such as alterations 
in AKT1/2, PIK3R1, LKB1, or NF1, or were using improper 
assays or thresholds. Second, tumors described as having 
PI3K alterations may not have responded because of the 
coexistence of mutations related to resistance, such as muta-
tions in KRAS,51,140 intratumor heterogeneity,75 or the use of 
incorrectly standardized or unvalidated assays. Finally, an 
important recent study designed to decipher whether action-
able driver mutations are found in all, or a subset of tumor 
cells found that 15% of mutations in genes of the PI3K/AKT/
mTOR signaling axis across all tumor types were subclonal, 
rather than truncal.141 This frequent presence of subclonal 
driver mutations in the PI3K/AKT/mTOR signaling axis 
may explain the inconclusive predictive value of these muta-
tions and suggests the need to stratify PI3K-directed therapy 
response according to the proportion of tumor cells in which 
the driver mutation is identified.141
In a study of .1600 patients with diverse advanced can-
cers enrolling onto phase I trials, PIK3CA mutations and/or 
PTEN aberrations were detected in ∼20% of patients.142 PTEN 
aberrations were mostly determined by loss of staining on 
immunohistochemistry (95% of patients with PTEN aberra-
tion), as only 5% of patients were tested for PTEN mutations. 
They also demonstrated that, in colorectal and gynecological 
cancers, PIK3CA mutations often coexisted with mutations 
in the MAPK pathway such as KRAS and BRAF muta-
tions, which can abrogate response to PI3K/AKT/mTOR 
pathway inhibitors.95,142–145
Levels of phosphorylated S6K and AKT may be pre-
dictive biomarkers for inhibitors of the mTOR pathway. 
Indeed a high level of phosphorylated S6K has been asso-
ciated with poor prognosis, and the levels of phosphory-
lated S6K and AKT have been shown to predict a favorable 
response to rapamycin or rapamycin analogs in breast cancer 
cells lines and other tumors.146–148 Furthermore, high lev-
els of phosphorylated AKT, GSK3β, and TSC2 have also 
been demonstrated to correlate with increased sensitivity to 
RAD001 (everolimus).149
Another potential predictive biomarker is INPP4B, 
a tumor suppressor that regulates PI3K/AKT. Its deletion may 
be seen with PTEN loss and it correlates with poor prognosis. 
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Tumors with INPP4B loss may also be candidates for targeting 
with PI3K inhibitors.150
It must be remembered that in addition to their direct 
therapeutic action on cancer cells, PI3K inhibitors can have 
effects on tumor angiogenesis, immune cells, and other 
tumor microenvironmental interactions; hence, it is con-
ceivable that there may not be a single biomarker of sensi-
tivity but rather a predictive molecular signature. Critical 
information will come from molecular profiling of clinical 
tumor material, including global cancer genome sequencing 
and gene expression analysis, followed by the correlation of 
such data with therapeutic response and outcome to various 
PI3K inhibitors.
conclusions
The PI3K pathway is one of the most commonly deregulated 
in cancer and is currently a major focus for anticancer drug 
development. As cancer medicine moves toward an increas-
ingly personalized paradigm, PI3K pathway inhibitors are 
likely to form a critical part of the therapeutic strategy for 
many cancers. For these drugs to be optimally used, it is of 
critical importance that early-phase trials include compre-
hensive PD evaluation as part of a broader strategy incorpo-
rating PK, predictive, and pharmacogenetic biomarkers. It 
is clear from the studies conducted to date that a multimo-
dality PD approach is optimal, evaluating both inhibition of 
phosphorylation of downstream proteins and also the meta-
bolic and immunological effects of the drug. Increasingly, 
technological advances in functional imaging and circulat-
ing biomarkers (eg, ctDNA) will allow for more detailed 
PD evaluation.
As the studies described in this review have largely 
demonstrated, use of single-agent PI3K pathway inhibi-
tors is usually associated with modest therapeutic eff icacy. 
These drugs are more likely to be optimally used in com-
bination with other molecularly targeted THERAPIES, 
cytotoxics, or hormonal therapies. Preclinical modeling 
and molecular profiling strategies will help determine 
the most effective combinations, with increasing use of 
patient-derived tissue to allow a more personalized thera-
peutic strategy. PD biomarkers will be critical in helping 
to determine optimal dosing by allowing assessment of 
differing dosing regimens, including pulsatile schedules, 
which could potentially offset the toxicity concerns around 
many PI3K combination regimens.
In conclusion, comprehensive PD evaluation together 
with robust predictive biomarkers is likely to be critical to the 
successful development of PI3K pathway inhibitors and for 
their integration into personalized treatment strategies.
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